Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
-
Patent office rejects J&J arm’s plea for HIV drug intermediate – Courtesy (Financial Express)
Pharma Live, , Intellectual Property Rights, 0
In a setback to US consumer health behemoth Johnson & Johnson, India’s patent office has rejected an application from...
-
Review on Development of Orphan Drug for Rare disease
Pharma Live, , Intellectual Property Rights, 0
ABOUT AUTHORS:Kamshette Sharada*, Poul Bhagwat, Ghodke AmolDepartment of Quality Assurance,Maharashtra College of Pharmacy,Nilanga, Maharashtra, India.*[email protected] ABSTRACTSimply receiving a diagnosis...
-
FDA Announces Major Proposed Rule Amending Hatch-Waxman Regulations – Courtesy (Hogan Lovells)
Pharma Live, , Intellectual Property Rights, 0
On February 6, 2015, the Food and Drug Administration (FDA) published in the Federal Register (FR) a comprehensive proposed...
-
The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0167629610001219-mainDownload
-
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s016885100900325x-mainDownload
-
Vanda gets favorable Markman ruling in Fanapt patent infringement litigation
Pharma Live, , Intellectual Property Rights, 0
WashingtonSaturday, September 12, 2015, 17:00 Hrs Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a favourable Markman ruling...
-
Judge Finds Biosimilar Patent Procedures Optional – Courtesy (Pharma Patent)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 23 MARCH 2015POSTED IN BIOSIMILARSJudge Seeborg of the U.S. District Court for the Northern District of...
-
It’s not just big pharma that wants to see IPR reform in US patent legislation – By Richard Lloyd
Pharma Live, , Intellectual Property Rights, 0
For over an hour yesterday, as the Senate Judiciary Committee hearing on the recently introduced PATENT Act unfolded, it seemed like we were...